Put companies on watchlist
Sensirion Holding AG
ISIN: CH0406705126
WKN: A2JGBW
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Sensirion Holding AG · ISIN: CH0406705126 · EQS - Company News (88 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1898195
08 May 2024 08:08AM

miniature liquid flow sensor platform for subcutaneous drug delivery


Sensirion Holding AG / Key word(s): Miscellaneous
Media Release: Sensirion product announcement: miniature liquid flow sensor platform for subcutaneous drug delivery

08.05.2024 / 08:08 CET/CEST


Media Release

08.05.2024, Sensirion AG, 8712 Stäfa, Schweiz

 

Sensirion product announcement: miniature liquid flow sensor platform for subcutaneous drug delivery

In the changing landscape of the healthcare industry, Sensirion's SLD3x series contributes to the improvement of subcutaneous drug delivery with miniature, and highly accurate digital liquid flow sensors. Customizable solutions ensure optimal dosing and enhanced patient safety for various subcutaneous therapies.

Stäfa, Switzerland – The healthcare industry has undergone a significant transformation in recent years, with an increasing focus on patient and home care. This shift has been mirrored in the field of drug administration, with a decrease in hospital stays for certain treatments. The transition from intravenous to subcutaneous injections using large volume injectors (LVIs) has been a key driver of this change.

LVIs are wearable devices that enable continuous subcutaneous drug delivery. They reduce pressure on clinical staff, save costs, and improve patient comfort. Some LVIs require precise dosing of the delivered drug, which in turn requires the pump to be controlled by a flow sensor. Moreover, bubbles, empty lines, occlusion detection, and drug delivery confirmation are desirable to improve patient safety and the regulatory compliance of the device.

To meet these needs, Sensirion is developing the SLD3x platform – a series of digital liquid flow sensors to combine accurate flow measurement, miniature size, and compatibility with several therapies. This makes it the ideal solution for medical devices manufactured in large quantities, where an accurate, disposable liquid flow sensor is required. While flow measurement is at the heart of the SLD3x platform, it also provides a stream of data that can be used to detect occlusions, identify in-line air bubbles, flag up pump malfunctions and measure liquid temperature.

“The SLD3x series features models with maximum flow rates ranging from 100 µl/min to 5 ml/min to meet the varying dosing requirements of different drugs and treatment protocols. We are happy to discuss the customization of sensors to meet the unique needs of specific therapies.” says Dr. Konrad Domanski, Product Director Liquid Flow Sensors at Sensirion.
 

For more information, please visit our product page or join our live webinar on May 23rd.

 

SLD3x series at a glance:

Full scale flow rate (H2O)                 5 ml/min          
Accuracy (H2O)                                5 %                 
Maximum operating pressure          3 bar   
Fluidic connector ports                    Downmount     
Supply voltage                                 3.2 - 3.8 V        
Size (LxWxH)                                    12 x 12 x 3.2 mm3


 

About Sensirion – Experts for Environmental and Flow Sensor Solutions

Sensirion is one of the world’s leading developers and manufacturers of sensors and sensor solutions that improve efficiency, health, safety, and comfort. Founded in 1998, Sensirion now employs around 1’200 people at its headquarters in Stäfa, Switzerland and in numerous international subsidiaries. Sensirion sensors can be used to measure a wide range of environmental parameters and flow rates precisely and reliably. The company’s aim is to make the world smarter with advanced sensor technology. As a pioneer in innovation, Sensirion develops solutions for the specific needs of customers and partners from the automotive, industrial, medical technology and consumer electronics markets, as well as high-quality products for cost-efficient mass production. More information and current key figures are available at www.sensirion.com.


Additional features:

File: Sensirion SLD3x Platform


End of Media Release


Language: English
Company: Sensirion Holding AG
Laubisrütistrasse 50
8712 Stäfa
Switzerland
Phone: +41 44 306 40 00
Fax: +41 44 306 49 06
Internet: www.sensirion.com
ISIN: CH0406705126
Valor: A2JGBW
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; SIX Swiss Exchange
EQS News ID: 1898195

 
End of News EQS News Service

1898195  08.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1898195&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Sensirion Holding AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.